Stoke Therapeutics, Inc. (STOK) Free cash flow 2018–2025
Stoke Therapeutics, Inc. (STOK) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
$44.9MFY2025 · since FY2018: -$11.9M → $44.9M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $44.9M | +151.6% |
| FY2024 | -$87.1M | -5.3% |
| FY2023 | -$82.7M | -130.8% |
| FY2022 | -$35.8M | +47.4% |
| FY2021 | -$68.1M | -57.4% |
| FY2020 | -$43.3M | -32.4% |
| FY2019 | -$32.7M | -174.7% |
| FY2018 | -$11.9M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More STOK financial trends
STOK RevenueSTOK Net incomeSTOK Net marginSTOK Gross profitSTOK Gross marginSTOK Operating incomeSTOK Operating marginSTOK Operating cash flowSTOK Capital expendituresSTOK Return on equitySTOK Stock buybacksSTOK Dividends paidSTOK Total assetsSTOK Total liabilitiesSTOK Shareholders’ equitySTOK overview →